Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less intensive, reduced chemotherapy treatment approach is currently being evaluated in the CompassHER2 pCR trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).

Facebook Comments